Patients diagnosed with rhabdomyosarcoma are treated with chemotherapy, radiotherapy and surgery, but many do not survive. Our United Kingdom and European colleagues have developed a new overarching trial, FaR-RMS study, which includes optimising radiotherapy, testing the latest promising agents, new combinations and analysing the length of therapy. Several research questions are addressed within FaR-RMS and new drugs can be rapidly added. Opening Far-RMS in Australia gives new hope to all patients battling rhabdomyosarcoma.
Disease Stage: Newly diagnosed, relapsed and progressive
Patient Age Range: All ages
Recruitment Period: Up to 7 years
- International: University of Birmingham
- National: ANZCHOG